The global oncology market is valued at approximately USD 250 billion to USD 280 billion, and it is projected to expand significantly toward multi-billion-dollar valuations over the next decade. Driven by an increasing global prevalence of cancer cases, rising healthcare expenditures, and rapid technological innovations in precision medicine, liquid biopsies, and targeted immunotherapies, the sector represents one of the largest and most heavily funded therapeutic areas within modern biopharmaceuticals.